MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
9.33
+0.22
+2.41%
Opening 11:45 05/07 EDT
OPEN
9.30
PREV CLOSE
9.11
HIGH
9.41
LOW
8.77
VOLUME
34.20K
TURNOVER
--
52 WEEK HIGH
17.00
52 WEEK LOW
6.71
MARKET CAP
399.57M
P/E (TTM)
119.92
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MAZE last week (0428-0502)?
Weekly Report · 2d ago
Weekly Report: what happened at MAZE last week (0421-0425)?
Weekly Report · 04/28 12:59
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/25 12:09
Weekly Report: what happened at MAZE last week (0414-0418)?
Weekly Report · 04/21 12:58
Weekly Report: what happened at MAZE last week (0407-0411)?
Weekly Report · 04/14 12:40
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 04/11 12:14
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/11 09:16
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 04/08 12:35
More
About MAZE
More
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Recently
Symbol
Price
%Change

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.